Leading developer
Eun-Ju Ryu has joined as President of Samyang Biopharm USA, a global biotech subsidiary of South Koreabased Samyang Holdings Corp in 2022. Ryu brings over 30 years of experience in the biopharmaceutical industry to her leadership position at Samyang Biopharm USA. Prior to this appointment she held a series of escalating management positions in various companies, including 12 years at Pfizer Inc. (USA) and 6 years at Pfizer Korea. Her career started as a regulatory manager, then expanded roles in clinical trial management team, business development and global marketing.
“I HOPE THAT 2022 WILL BE A YEAR OF OVERCOMING THE PANDEMIC AND RESTORING DAILY LIFE BY COMBINING THE EFFORTS OF MANY RESEARCHERS.”